BRIEF—Semaglutide patent win for Novo Nordisk

Novo Nordisk’s American traded shares rose 1% after the Danish diabetes care giant won two patent challenges related to semaglutide, its best-selling weight-loss therapy, Wegovy, also marketed as Ozempic for diabetes.

Novo Nordisk convinced an administrative tribunal to shoot down challenges to two of its patents for the active compound in its blockbuster drugs Ozempic and Wegovy, according to media reports.

The US Patent and Trademark Office’s Patent Trial and Appeal Board ruled Monday that Mylan Pharmaceuticals did not meet the requirements for an inter partes review of US Patent Nos 8,536,122 and 8,129,343.

The patents encompass semaglutide, the active ingredient in the drugs, according to the PTAB’s rulings.